ObsEva SA Company Profile (NASDAQ:OBSV)

About ObsEva SA (NASDAQ:OBSV)

ObsEva SA logoObseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women's reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea. OBE001 (nolasiban) is an oral, new generation oxytocin antagonist with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART). BE022 is an orally active small molecule dinoprost (PGF2a) receptor antagonist.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OBSV
  • CUSIP: N/A
  • Web: www.obseva.com
Capitalization:
  • Market Cap: $228.16 million
  • Outstanding Shares: 28,496,000
Average Prices:
  • 50 Day Moving Avg: $7.04
  • 200 Day Moving Avg: $7.04
  • 52 Week Range: $6.77 - $14.18
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.94
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.38 per share
  • Price / Book: 2.28
Profitability:
  • EBIDTA: ($52,850,000.00)
Debt:
  • Current Ratio: 12.08%
  • Quick Ratio: 12.08%
Misc:
  • Average Volume: 21,343 shs.
  • Short Ratio: 0.22
 

Frequently Asked Questions for ObsEva SA (NASDAQ:OBSV)

What is ObsEva SA's stock symbol?

ObsEva SA trades on the NASDAQ under the ticker symbol "OBSV."

How were ObsEva SA's earnings last quarter?

ObsEva SA (NASDAQ:OBSV) posted its quarterly earnings data on Tuesday, August, 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.13. During the same quarter in the prior year, the firm posted ($0.30) EPS. View ObsEva SA's Earnings History.

When will ObsEva SA make its next earnings announcement?

ObsEva SA is scheduled to release their next quarterly earnings announcement on Tuesday, November, 21st 2017. View Earnings Estimates for ObsEva SA.

Where is ObsEva SA's stock going? Where will ObsEva SA's stock price be in 2017?

5 brokerages have issued 1-year target prices for ObsEva SA's stock. Their forecasts range from $18.00 to $27.00. On average, they expect ObsEva SA's stock price to reach $23.00 in the next twelve months. View Analyst Ratings for ObsEva SA.

What are analysts saying about ObsEva SA stock?

Here are some recent quotes from research analysts about ObsEva SA stock:

  • 1. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (9/21/2017)
  • 2. Jefferies Group LLC analysts commented, "We view OBSV shares as attractive based on lead asset OBE2109 in two prevalent gynecologic conditions. We see the dev'l strategy and superior PK profile of OBE2109 supportive of best-in-class pot'l. The stock is undervalued in our opinion as it trades at a 2x discount to its closest competitor, despite an experienced mgmt team w/ a proven track record in women's health. We initiate with a Buy rating and a $21 PT." (2/21/2017)

Who are some of ObsEva SA's key competitors?

Who are ObsEva SA's key executives?

ObsEva SA's management team includes the folowing people:

  • Frank Verwiel M.D., Independent Chairman of the Board
  • Ernest Loumaye M.D., Ph.D., Chief Executive Officer, Director
  • Timothy M. Adams, Chief Financial Officer
  • Jean-Pierre Gotteland Ph.D., Chief Scientific Officer
  • Fabien Lefebvre de Ladonchamps, Vice President - Finance
  • Ben T.G. Tan, Vice President - Commercial & Business Development
  • Elke Bestel, Chief Medical Officer and Head of Pharmacovigilance
  • Nanna Luneborg Ph.D., Director
  • Annette V. Clancy, Independent Director
  • Barbara G. Duncan, Independent Director

When did ObsEva SA IPO?

(OBSV) raised $98 million in an IPO on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

Who owns ObsEva SA stock?

ObsEva SA's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sofinnova Management VIII L.L.C. (12.65%), NEA Management Company LLC (12.53%), MEDICXI GROWTH I LP (5.30%), NOVO HOLDINGS A (3.10%), Sphera Funds Management LTD. (0.87%) and Sectoral Asset Management Inc (0.80%). View Institutional Ownership Trends for ObsEva SA.

Who sold ObsEva SA stock? Who is selling ObsEva SA stock?

ObsEva SA's stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Nexthera Capital LP and UBS Oconnor LLC. View Insider Buying and Selling for ObsEva SA.

Who bought ObsEva SA stock? Who is buying ObsEva SA stock?

ObsEva SA's stock was acquired by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Sectoral Asset Management Inc and Sphera Funds Management LTD.. View Insider Buying and Selling for ObsEva SA.

How do I buy ObsEva SA stock?

Shares of ObsEva SA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ObsEva SA's stock price today?

One share of ObsEva SA stock can currently be purchased for approximately $7.70.


MarketBeat Community Rating for ObsEva SA (NASDAQ OBSV)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  98
MarketBeat's community ratings are surveys of what our community members think about ObsEva SA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ObsEva SA (NASDAQ:OBSV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.00 (198.70% upside)

Analysts' Ratings History for ObsEva SA (NASDAQ:OBSV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/14/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$22.00LowView Rating Details
9/8/2017HC WainwrightReiterated RatingBuy$27.00LowView Rating Details
8/16/2017Leerink SwannReiterated RatingOutperform -> Outperform$18.00HighView Rating Details
4/18/2017Credit Suisse GroupReiterated RatingOutperform$27.00LowView Rating Details
2/21/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$21.00N/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for ObsEva SA (NASDAQ:OBSV)
Earnings by Quarter for ObsEva SA (NASDAQ:OBSV)
Earnings History by Quarter for ObsEva SA (NASDAQ OBSV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/21/2017        
8/15/20176/30/2017($0.48)($0.61)$0.01 millionViewN/AView Earnings Details
5/18/20173/31/2017($0.41)($0.58)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ObsEva SA (NASDAQ:OBSV)
2017 EPS Consensus Estimate: ($2.18)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.41)($0.32)($0.37)
Q2 20172($0.46)($0.46)($0.46)
Q3 20172($0.67)($0.65)($0.66)
Q4 20172($0.71)($0.68)($0.70)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ObsEva SA (NASDAQ:OBSV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ObsEva SA (NASDAQ:OBSV)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for ObsEva SA (NASDAQ:OBSV)
Latest Headlines for ObsEva SA (NASDAQ:OBSV)
Source:
DateHeadline
americanbankingnews.com logoZacks Investment Research Upgrades ObsEva SA (OBSV) to "Hold"
www.americanbankingnews.com - September 23 at 5:22 PM
americanbankingnews.com logoRoyal Bank Of Canada Begins Coverage on ObsEva SA (OBSV)
www.americanbankingnews.com - September 14 at 10:35 PM
americanbankingnews.com logoObsEva SA (OBSV) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 14 at 10:22 PM
finance.yahoo.com logoObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting
finance.yahoo.com - September 12 at 7:42 AM
americanbankingnews.com logoObsEva SA (OBSV) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - September 9 at 8:52 PM
americanbankingnews.com logoObsEva SA (OBSV) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - September 8 at 6:44 PM
nasdaq.com logoObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in
www.nasdaq.com - September 7 at 7:06 AM
finance.yahoo.com logoObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of Schedule
finance.yahoo.com - September 6 at 7:07 AM
finanznachrichten.de logoObsEva SA: ObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYC
www.finanznachrichten.de - August 30 at 7:31 AM
finance.yahoo.com logoObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYC
finance.yahoo.com - August 30 at 7:31 AM
americanbankingnews.com logoZacks: ObsEva SA (OBSV) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - August 29 at 2:50 PM
americanbankingnews.com logoObsEva SA (OBSV) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - August 27 at 8:50 AM
americanbankingnews.com logoObsEva SA (OBSV) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - August 19 at 10:20 AM
finance.yahoo.com logoEdited Transcript of OBSV.O earnings conference call or presentation 15-Aug-17 9:00pm GMT
finance.yahoo.com - August 19 at 6:10 AM
americanbankingnews.com logoObsEva SA Forecasted to Post Q3 2017 Earnings of ($0.65) Per Share (OBSV)
www.americanbankingnews.com - August 18 at 6:42 AM
americanbankingnews.com logoObsEva SA (OBSV) Forecasted to Post Q3 2017 Earnings of ($0.67) Per Share
www.americanbankingnews.com - August 18 at 6:42 AM
americanbankingnews.com logoObsEva SA's (OBSV) "Outperform" Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - August 16 at 1:06 PM
americanbankingnews.com logoObsEva SA (OBSV) PT Set at $27.00 by HC Wainwright
www.americanbankingnews.com - August 16 at 8:02 AM
rttnews.com logoALXN's Strengthening Patents, FOLD's Fabry Drug Approved In OZ, VBIV Surges
www.rttnews.com - August 16 at 2:42 AM
americanbankingnews.com logoObsEva SA (OBSV) Releases Quarterly Earnings Results, Misses Estimates By $0.13 EPS
www.americanbankingnews.com - August 15 at 7:26 PM
finance.yahoo.com logoObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 15 at 4:39 PM
americanbankingnews.com logoZacks: ObsEva SA (NASDAQ:OBSV) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - August 13 at 10:40 AM
americanbankingnews.com logoObsEva SA (OBSV) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - August 8 at 10:44 AM
feeds.benzinga.com logoObsEva SA to Hold Second Quarter 2017 Financial Results/Business Update Call on August 15, 2017 and Present at Wedbush PacGrow Healthcare Conference in NYC on August 16, 2017
feeds.benzinga.com - August 7 at 7:16 AM
americanbankingnews.com logoBrokerages Anticipate ObsEva SA (OBSV) to Announce ($0.48) Earnings Per Share
www.americanbankingnews.com - August 4 at 8:18 AM
americanbankingnews.com logoComparing ObsEva SA (NASDAQ:OBSV) and Bellicum Pharmaceuticals (BLCM)
www.americanbankingnews.com - July 22 at 4:10 PM
americanbankingnews.com logoObsEva SA's (OBSV) Lock-Up Period Will Expire on July 25th
www.americanbankingnews.com - July 18 at 11:13 AM
americanbankingnews.com logoAnalyzing Eleven Biotherapeutics (EBIO) and ObsEva SA (OBSV)
www.americanbankingnews.com - July 4 at 8:24 AM
finance.yahoo.com logoObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting
finance.yahoo.com - June 30 at 2:51 AM
americanbankingnews.com logo ObsEva SA (OBSV) Given $21.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - June 29 at 8:54 PM
americanbankingnews.com logoObsEva SA (OBSV) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - June 29 at 7:34 AM
americanbankingnews.com logo Analysts Anticipate ObsEva SA (OBSV) to Announce -$0.54 EPS
www.americanbankingnews.com - June 29 at 12:18 AM
finance.yahoo.com logoWhat Falling Estimates & Price Mean for ObsEva (OBSV)
finance.yahoo.com - June 16 at 8:27 AM
americanbankingnews.com logo ObsEva SA (OBSV) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - June 14 at 4:32 PM
americanbankingnews.com logo Brokerages Anticipate Obseva SA (OBSV) to Post -$0.54 EPS
www.americanbankingnews.com - June 2 at 10:28 PM
americanbankingnews.com logoObseva SA (OBSV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 30 at 8:12 AM
americanbankingnews.com logoBrokerages Expect Obseva SA (OBSV) to Post ($0.54) Earnings Per Share
www.americanbankingnews.com - May 26 at 8:43 PM
americanbankingnews.com logoObseva SA (OBSV) Issues Earnings Results
www.americanbankingnews.com - May 19 at 9:23 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Obseva SA (OBSV) to Announce -$0.41 EPS
www.americanbankingnews.com - May 9 at 12:30 PM
americanbankingnews.com logo Obseva SA (OBSV) Given $21.00 Average Target Price by Brokerages
www.americanbankingnews.com - May 5 at 11:38 AM
americanbankingnews.com logoJefferies Group Comments on Obseva SA's Q1 2017 Earnings (OBSV)
www.americanbankingnews.com - April 26 at 8:33 AM
americanbankingnews.com logoObseva SA (OBSV) Earns "Outperform" Rating from Credit Suisse Group AG
www.americanbankingnews.com - April 24 at 1:10 PM
americanbankingnews.com logoAnalysts Expect Obseva SA (OBSV) to Announce ($0.35) Earnings Per Share
www.americanbankingnews.com - April 20 at 9:47 AM
americanbankingnews.com logoObseva SA (OBSV) Expected to Post Earnings of -$0.35 Per Share
www.americanbankingnews.com - April 18 at 4:34 PM
americanbankingnews.com logoObseva SA's (OBSV) Outperform Rating Reiterated at Credit Suisse Group AG
www.americanbankingnews.com - April 18 at 2:08 PM
americanbankingnews.com logoObseva SA (OBSV) Coverage Initiated by Analysts at Jefferies Group LLC
www.americanbankingnews.com - March 26 at 2:25 PM
americanbankingnews.com logoLeerink Swann Begins Coverage on Obseva SA (OBSV)
www.americanbankingnews.com - March 26 at 12:31 PM
finance.yahoo.com logoObsEva SA to Attend Needham Annual Healthcare Conference in NYC
finance.yahoo.com - March 24 at 6:53 PM
finance.yahoo.com logoObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination …
finance.yahoo.com - March 18 at 12:09 AM
streetinsider.com logoObsEva (OBSV) Says OBE022 Observed to Exert Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor
www.streetinsider.com - March 18 at 12:09 AM

Social

Chart

ObsEva SA (OBSV) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff